Proadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia | Zendy

Todd A. Florin | Zendy; Lilliam Ambroggio | Zendy; Cole Brokamp | Zendy; Yin Zhang | Zendy; Eric Nylén | Zendy; Mantosh S. Rattan | Zendy; Eric J. Crotty | Zendy; Michael A. Belsky | Zendy; Sara Krueger | Zendy; Thomas N. Epperson | Zendy; Andrea Kachelmeyer | Zendy; Richard M. Ruddy | Zendy; Samir S. Shah | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Proadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia

Author(s) -

Todd A. Florin,

Lilliam Ambroggio,

Cole Brokamp,

Yin Zhang,

Eric Nylén,

Mantosh S. Rattan,

Eric J. Crotty,

Michael A. Belsky,

Sara Krueger,

Thomas N. Epperson,

Andrea Kachelmeyer,

Richard M. Ruddy,

Samir S. Shah

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa1138

Subject(s) - medicine , pneumonia , community acquired pneumonia , intensive care medicine , disease , pediatrics

Proadrenomedullin (proADM), a vasodilatory peptide with antimicrobial and anti-inflammatory properties, predicts severe outcomes in adults with community-acquired pneumonia (CAP) to a greater degree than C-reactive protein and procalcitonin. We evaluated the ability of proADM to predict disease severity across a range of clinical outcomes in children with suspected CAP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research